[go: up one dir, main page]

WO2007001067A3 - Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker - Google Patents

Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker Download PDF

Info

Publication number
WO2007001067A3
WO2007001067A3 PCT/JP2006/313176 JP2006313176W WO2007001067A3 WO 2007001067 A3 WO2007001067 A3 WO 2007001067A3 JP 2006313176 W JP2006313176 W JP 2006313176W WO 2007001067 A3 WO2007001067 A3 WO 2007001067A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
solid dosage
angiotensin
receptor antagonist
calcium channel
Prior art date
Application number
PCT/JP2006/313176
Other languages
French (fr)
Other versions
WO2007001067A2 (en
Inventor
Takeshi Hamaura
Mitsuru Kanno
Original Assignee
Daiichi Sankyo Co Ltd
Takeshi Hamaura
Mitsuru Kanno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Takeshi Hamaura, Mitsuru Kanno filed Critical Daiichi Sankyo Co Ltd
Priority to JP2007558257A priority Critical patent/JP5110697B2/en
Publication of WO2007001067A2 publication Critical patent/WO2007001067A2/en
Publication of WO2007001067A3 publication Critical patent/WO2007001067A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a solid dosage form comprising an angiotensin II receptor antagonist and a calcium channel blocker, wherein the active ingredients are formulated such that they are not intimately mixed in said solid dosage form. The solid dosage form demonstrates improved dissolution properties.
PCT/JP2006/313176 2005-06-27 2006-06-26 Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker WO2007001067A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007558257A JP5110697B2 (en) 2005-06-27 2006-06-26 Solid preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005187214 2005-06-27
JP2005-187214 2005-06-27

Publications (2)

Publication Number Publication Date
WO2007001067A2 WO2007001067A2 (en) 2007-01-04
WO2007001067A3 true WO2007001067A3 (en) 2007-07-12

Family

ID=37460221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/313176 WO2007001067A2 (en) 2005-06-27 2006-06-26 Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Country Status (3)

Country Link
JP (2) JP5110697B2 (en)
TW (1) TWI388345B (en)
WO (1) WO2007001067A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469753B1 (en) 1996-05-03 2002-10-22 Starsight Telecast, Inc. Information system
GT200600371A (en) * 2005-08-17 2007-03-21 SOLID DOSE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD TO DO THE SAME
US9113107B2 (en) 2005-11-08 2015-08-18 Rovi Guides, Inc. Interactive advertising and program promotion in an interactive television system
CN101478966B (en) * 2006-06-27 2013-08-21 第一三共株式会社 Compressed preparation
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
US8832742B2 (en) 2006-10-06 2014-09-09 United Video Properties, Inc. Systems and methods for acquiring, categorizing and delivering media in interactive media guidance applications
KR101247583B1 (en) * 2006-12-08 2013-03-26 한미사이언스 주식회사 Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof
TWI402083B (en) * 2006-12-26 2013-07-21 Daiichi Sankyo Co Ltd Solid dosage form and stabilization method thereof
TWI414310B (en) * 2006-12-26 2013-11-11 Daiichi Sankyo Co Ltd Elution-improved pharmaceutical preparation
TWI488658B (en) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd Method for improvement of elution
ES2817504T3 (en) * 2008-01-25 2021-04-07 Laboratoires Majorelle Oral Drug Combinations Bound by an Envelope
JP5554699B2 (en) * 2008-03-13 2014-07-23 第一三共株式会社 Improving dissolution properties of formulations containing olmesartan medoxomil
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
BRPI0924136B8 (en) * 2009-01-23 2021-05-25 Hanmi Holdings Co Ltd solid pharmaceutical composition comprising amlodipine and losartan and method for preparing the same
PE20121131A1 (en) * 2009-06-30 2012-09-04 Sanofi Sa SOLID ORAL PHARMACEUTICAL COMPOSITION IN MONOCAPA TABLET INCLUDING IRBESARTAN AND AMLODIPINE BESYLATE
JP5886530B2 (en) * 2010-02-26 2016-03-16 第一三共株式会社 tablet
JP5421945B2 (en) * 2010-03-10 2014-02-19 大日本住友製薬株式会社 Pharmaceutical composition containing irbesartan and amlodipine or a salt thereof
JP5824222B2 (en) * 2010-03-31 2015-11-25 第一三共株式会社 Method for producing solid preparation
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
UY33772A (en) 2010-12-09 2012-07-31 Lg Life Sciences Ltd PHARMACEUTICAL COMPOSITION THAT INCLUDES LERCANIDIPINE CHLORHYDRATE AND VALSARTAN AS ACTIVE COMPONENTS AND TO A METHOD FOR THE PREPARATION OF THE SAME.
JP6041591B2 (en) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 Stabilized pharmaceutical composition comprising irbesartan and amlodipine or a salt thereof
JP5854371B2 (en) * 2012-10-12 2016-02-09 味の素株式会社 Pharmaceutical preparation containing calcium antagonist / angiotensin II receptor antagonist
MX2013001277A (en) * 2013-01-31 2014-07-30 Miguel Ángel García Pérez Pharmaceutical composition comprising an angiotensin ii-receptor antagonist and a calcium channel blocker for the treatment of arterial hypertension.
CN103127110A (en) * 2013-03-18 2013-06-05 吉林省博大伟业制药有限公司 Compound preparation containing angiotensin II receptor antagonist and calcium channel blocker
CN103271908B (en) * 2013-05-23 2019-02-12 浙江华海药业股份有限公司 Oral tablet and preparation method thereof containing Telmisartan and Amlodipine Besylate Tablet
EP3025711B1 (en) * 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medicine for preventing or treating hypertension
CN103908539B (en) * 2014-05-03 2017-02-01 李全浩 Traditional Chinese medicine composition for treating hypertension as well as preparation method and application of traditional Chinese medicine composition
CN104000821B (en) * 2014-06-02 2020-06-19 浙江华海药业股份有限公司 Oral double-layer tablet containing telmisartan and amlodipine besylate and preparation method thereof
WO2016114725A1 (en) * 2015-01-12 2016-07-21 İlko İtaç Sanayi Ve Ticaret Anonim Şirketi A stable bilayer pharmaceutical tablet compositions comprising fixed dose of irbesartan and amlodipine
JP6934859B2 (en) * 2016-03-24 2021-09-15 第一三共株式会社 Medicines for the treatment of kidney disease
CN109432034A (en) * 2018-12-28 2019-03-08 乐普制药科技有限公司 A kind of valsartan amlodipine tri-layer tablets and preparation method thereof
CN110237073B (en) * 2019-07-10 2022-12-02 安庆回音必制药股份有限公司 Olmesartan medoxomil amlodipine tablet and preparation method thereof
CN114712319B (en) * 2022-03-25 2024-01-09 北京诺康达医药科技股份有限公司 Felodipine and propranolol hydrochloride compound preparation and preparation method thereof
CN115227662B (en) * 2022-06-24 2023-11-24 辰欣药业股份有限公司 Valsartan amlodipine tablet and preparation method thereof
CN115944600B (en) * 2022-12-01 2024-05-28 山东齐都药业有限公司 Oral tablet containing telmisartan and amlodipine besylate and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049384A1 (en) * 1999-07-08 2001-12-06 Webb Randy Lee Method of treatment and pharmaceutical composition
WO2003059327A1 (en) * 2002-01-16 2003-07-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
WO2003080057A1 (en) * 2002-03-27 2003-10-02 Bayer Aktiengesellschaft Downsized core tablet containing nifedipine
WO2003097045A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of organic compounds
JP2004002348A (en) * 2002-03-27 2004-01-08 Bayer Yakuhin Ltd Miniaturized nifidipine nucleated tablet
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2006048208A1 (en) * 2004-11-05 2006-05-11 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0859470A (en) * 1994-08-29 1996-03-05 Sankyo Co Ltd Elution improving preparation of cyclopenta(alpha)pyrimidine derivative
JP2004300102A (en) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd Condensed heterocyclic derivative, pharmaceutical composition containing the same and its pharmaceutical application

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049384A1 (en) * 1999-07-08 2001-12-06 Webb Randy Lee Method of treatment and pharmaceutical composition
WO2003059327A1 (en) * 2002-01-16 2003-07-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
WO2003080057A1 (en) * 2002-03-27 2003-10-02 Bayer Aktiengesellschaft Downsized core tablet containing nifedipine
JP2004002348A (en) * 2002-03-27 2004-01-08 Bayer Yakuhin Ltd Miniaturized nifidipine nucleated tablet
WO2003097045A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of organic compounds
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2006048208A1 (en) * 2004-11-05 2006-05-11 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200381, Derwent World Patents Index; AN 2003-876879, XP002429031 *

Also Published As

Publication number Publication date
JP2008543729A (en) 2008-12-04
JP5456857B2 (en) 2014-04-02
TW200730202A (en) 2007-08-16
TWI388345B (en) 2013-03-11
JP2012236853A (en) 2012-12-06
JP5110697B2 (en) 2012-12-26
WO2007001067A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
WO2007001067A3 (en) Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
TW200740459A (en) Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker
WO2007001065A3 (en) Method for the preparation of a wet granulated drug product
WO2007019439A3 (en) Block copolymer compositions and uses thereof
IL195488A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
WO2007114926A3 (en) Kinase antagonists
WO2008057579A3 (en) Dosage forms and co-administration of an opioid agonist and an opioid antagonist
IL197831A (en) Human antibodies that bind cxcr4, compositions comprising the same and uses thereof
BRPI1011254A2 (en) "binder premix, binder mix, and concrete composition."
IL186089A0 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
MY157716A (en) Solid dosage form of olmesartan medoxomil and amlodipine
IL179595A0 (en) Substituted indazoles, compositions containing same, preparation and use
IL181618A0 (en) Pharmaceutical solid-in-oil compositions for external administraton, methods for preparation and uses thereof
SI1765327T1 (en) Compounds, compositions and methods
WO2007076260A3 (en) Farnesoid x receptor agonists
WO2007050802A3 (en) Novel opioid antagonists
IL202038A0 (en) Rna antagonist compounds, compositions comprising the same and uses thereof
IL196426A (en) Microparticles based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2007002823A3 (en) Formulations of conjugated estrogens and bazedoxifene
PL1791438T5 (en) Powdered, cold-water soluble/dispersible, foamable composition
WO2007044251A3 (en) Pharmaceutical compositions
WO2008113916A9 (en) Pharmaceutical composition containing antibodies directed against the herv-w envelope
IL192824A (en) Peptidic compounds, pharmaceutical compositions comprising them and uses thereof
EP1637167A3 (en) New injectable formulations containing progesterone
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2007558257

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06767754

Country of ref document: EP

Kind code of ref document: A2